

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors ID3813

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (asciminib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust • Anthony Nolan • Black Health Agency • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Myeloma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • WMUK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Haematology 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Blood and Transplant • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (dasatinib) • Incyte Corporation (ponatinib) • Novartis (imatinib) • Novartis (nilotinib) • Pfizer (bosutinib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Genomics England • Institute of Cancer Research • Leuka

Provisional stakeholder list for the health technology appraisal of asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors ID3813

Issue date: May 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Chronic Lymphocytic Leukaemia Forum • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society • United Kingdom Cutaneous Lymphoma Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bury CCG • NHS Calderdale CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Leukaemia Busters • Leukaemia UK • Lymphoma Research Trust • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.